BCA
TGTX icon

Berman Capital Advisors’s TG Therapeutics TGTX Stock Holding History

Berman Capital Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-210
Closed -$10K – 2043
2021
Q1 		$10K Buy
+210
New +$10.1K ﹤0.01% 1040

Other funds holding TGTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Berman Capital Advisors's TGTX Position: Q2 2021 in Review

Berman Capital Advisors sold out of TG Therapeutics (TGTX) in Q2 2021, closing a stake of 210 shares — an estimated $10K sold.

Berman Capital Advisors first reported a position in TGTX in Q1 2021 and held it in 1 quarter. The position peaked at $10K in Q1 2021. 237 funds tracked by Wall St. Rank hold TGTX as of Q2 2021.

  • Berman Capital Advisors reported no remaining TG Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Berman Capital Advisors sold 210 TG Therapeutics shares in Q2 2021, an estimated $10K.
  • Berman Capital Advisors first reported a position in TG Therapeutics in Q1 2021 and held it in 1 quarter.
  • Berman Capital Advisors's TG Therapeutics position peaked at $10K in Q1 2021.
  • 237 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2021.

Based on Berman Capital Advisors's 13F filing for Q2 2021, filed 11 Aug 2021.